Document Detail

Beneficial cardiovascular actions of eplerenone in the spontaneously hypertensive rat.
MedLine Citation:
PMID:  16211209     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Aldosterone has been implicated as a potential mediator of cardiac and vascular damage in a variety of disorders. This study examined the role of aldosterone and its interplay with the renin-angiotensin system in the pathogenesis of hypertension. To this end, the effects of the aldosterone antagonist eplerenone and the angiotensin converting enzyme inhibitor lisinopril on cardiovascular mass, myocardial collagen, and coronary circulation were examined in spontaneously hypertensive rats.
METHODS: Male, 22-week-old rats were randomly divided into 4 groups (12 in each). The control group received no treatment, the second group was given eplerenone (100 mg/kg/day), the third received lisinopril (3 mg/kg/day), and the fourth was given eplerenone and lisinopril. After 12 weeks of respective treatments, systemic and regional hemodynamics and cardiovascular mass indexes were measured in conscious instrumented rats.
RESULTS: Eplerenone decreased arterial pressure but did not affect left ventricular mass or hydroxyproline concentration (an estimate of collagen). It did, however, reduce minimal coronary vascular resistance and increased coronary flow reserve. Lisinopril decreased arterial pressure and ventricular mass but did not affect regional hemodynamics. The combination therapy produced synergistic effects.
CONCLUSION: Aldosterone antagonism improved coronary and systemic hemodynamics in adult spontaneously hypertensive rats but did not affect cardiovascular mass indexes. The finding that lisinopril and eplerenone decreased arterial pressure to the same extent but had different cardiovascular effects suggested that these effects might be pressure independent.
Dinko Susic; Jasmina Varagic; Jwari Ahn; Luis C Matavelli; Edward D Frohlich
Related Documents :
645899 - Aldosterone metabolism in isolated perfused rat kidney.
10601119 - Impeded alveolar-capillary gas transfer with saline infusion in heart failure.
9504349 - Hypertension and hypothyroidism.
11541179 - Effects of the renin-angiotensin-aldosterone system on the cardiovascular system during...
14604739 - Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patien...
17173239 - The kidney and hypertension: over 70 years of research.
889599 - Sustained reduction of cardiac impedance and preload in congestive heart failure with t...
1698129 - Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose pota...
9502639 - Differential effect of acute baroreceptor unloading on cardiac and systemic sympathetic...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  10     ISSN:  1074-2484     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-10-07     Completed Date:  2006-01-18     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  197-203     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects*
Coronary Circulation / drug effects
Hypertension / drug therapy*,  physiopathology
Lisinopril / pharmacology
Rats, Inbred SHR
Spironolactone / analogs & derivatives*,  pharmacology
Vascular Resistance / drug effects
Reg. No./Substance:
27O7W4T232/Spironolactone; 6995V82D0B/eplerenone; E7199S1YWR/Lisinopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking ...
Next Document:  Effectiveness of oral magnesium in a patient with ventricular tachycardia due to hypomagnesemia.